Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 4,709 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Signs and Symptoms, Respiratory Clear all
Terminated Phase 2Phase 3 Interventional

Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia

NCT00127387
View directory record Official record
Conditions
Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Interventions
Enbrel
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Not applicable Interventional Results available

Long QT Syndrome and Sleep Apnea

NCT03678311
View directory record Official record
Conditions
Long QT Syndrome, Sleep Apnea
Interventions
Continuous Positive Airway Pressure (CPAP)
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 3 Interventional

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

NCT00215436
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
44
States / cities
Jasper, Alabama • Phoenix, Arizona • Tuscon, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 2 Interventional Results available

Etirinotecan Pegol (NKTR-102) in NSCLC

NCT01773109
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Etirinotecan pegol (NKTR-102)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 24, 2026, 4:40 AM EDT
Recruiting Phase 2 Interventional

Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation

NCT06940609
View directory record Official record
Conditions
Long COVID, Long COVID Syndrome, Long COVID-19 Syndrome, PASC, PASC Post Acute Sequelae of COVID 19
Interventions
accelerated intermittent theta burst stimulation
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 24, 2026, 4:40 AM EDT
Not listed Not applicable Interventional

Inspiratory Muscle Training in COPD

NCT03438019
View directory record Official record
Conditions
COPD
Interventions
PrO2, Threshold Inspiratory Muscle Trainer
Device
Lead sponsor
Miami VA Healthcare System
Federal
Eligibility
40 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 24, 2026, 4:40 AM EDT
Terminated No phase listed Observational

Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)

NCT02769637
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PPI treatment
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 27, 2018 · Synced Oct 24, 2026, 4:40 AM EDT
Completed No phase listed Observational Results available

The Trajectory of Physical Activity Following Pulmonary Rehabilitation

NCT02399254
View directory record Official record
Conditions
COPD, Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Trinity Health Of New England
Other
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Hartford, Connecticut • Wallingford, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 24, 2026, 4:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

NCT01851642
View directory record Official record
Conditions
Alpha-1 Antitrypsin Deficiency, AAT Deficiency, AATD, Cystic Fibrosis (CF)
Interventions
History and physical exam., Blood draw., Pulmonary function testing., Albuterol inhaler.
Procedure · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2033
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ketorolac on Postoperative Pain Reduction in Pediatric Patients with Adenotonsillectomy

NCT05074056
View directory record Official record
Conditions
Adenotonsillar Hypertrophy, Obstructive Sleep Apnea, Sleep-Disordered Breathing, Acute Post Operative Pain
Interventions
Ketorolac
Drug
Lead sponsor
St. Louis University
Other
Eligibility
3 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 24, 2026, 4:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms

NCT01518322
View directory record Official record
Conditions
Asthma
Interventions
NIOX MINO®
Device
Lead sponsor
Aerocrine AB
Industry
Eligibility
7 Years to 65 Years
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
13
States / cities
Byron, Minnesota • Chatfield, Minnesota • Pine Island, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 2 Interventional

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00683722
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Pulmonary Emphysema, Chronic Bronchitis
Interventions
Prochymal™, Placebo
Drug
Lead sponsor
Mesoblast, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Torrance, California • Charlotte, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Yogurt Study in Children 2-4 Years Old Attending Daycare

NCT00760851
View directory record Official record
Conditions
Infections, Respiratory, Diarrhea
Interventions
probiotic strain Bb-12, no Bb-12
Other
Lead sponsor
Georgetown University
Other
Eligibility
2 Years to 4 Years
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2011 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Not applicable Interventional

Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN (V-TRaIN)

NCT02611531
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Video Module Education (VME), Teach-To-Goal (TTG)
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 24, 2026, 4:40 AM EDT
Withdrawn Phase 2 Interventional

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

NCT01451853
View directory record Official record
Conditions
Lung Cancer, Head and Neck Cancer, Hearing Loss, Ototoxicity, Tinnitus, Neuropathy
Interventions
SPI-1005 Low Dose, SPI-1005 Middle Dose, SPI-1005 High Dose, Placebo
Drug
Lead sponsor
Sound Pharmaceuticals, Incorporated
Industry
Eligibility
19 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

NCT02743351
View directory record Official record
Conditions
Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
Interventions
ProTmune, Control Arm
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 2 Interventional Results available

Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01402531
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Submucosal Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 3 Interventional

Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

NCT05742802
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tozorakimab 1, Tozorakimab 2, Placebo
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
46
States / cities
Sheffield, Alabama • Tempe, Arizona • Lincoln, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 24, 2026, 4:40 AM EDT
Not yet recruiting Not applicable Interventional

ADINA vs. High Flow Nasal Cannula Comparison Study

NCT03171129
View directory record Official record
Conditions
Respiratory Distress Neonatal
Interventions
Adaptive Dynamic Inspiratory Nasal Apparatus, High flow Nasal Canula
Device
Lead sponsor
Loma Linda University
Other
Eligibility
23 Weeks to 40 Weeks
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 24, 2026, 4:40 AM EDT
Completed No phase listed Observational

Connect Lung Outcomes With Bronchodilator Use

NCT04417842
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Respimetrix flow-volume monitoring device
Diagnostic Test
Lead sponsor
Pulmonary Critical Care Associates of Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Not applicable Interventional

A Six Month Randomized Controlled Clinical Trial of Lung Flute in Patients With Chronic Obstructive Pulmonary Disease

NCT01186822
View directory record Official record
Conditions
COPD
Interventions
Lung Flute
Device
Lead sponsor
Nicolaas J Smit PhD
Industry
Eligibility
30 Years to 80 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)

NCT04880161
View directory record Official record
Conditions
Covid19
Interventions
Ampion, Placebo
Biological · Other
Lead sponsor
Ampio Pharmaceuticals. Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Phase 3 Interventional Results available

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

NCT01899742
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium/Vilanterol 62.5/25 mcg, Tiotropium 18 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Medford, Oregon • Greenville, South Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 24, 2026, 4:40 AM EDT
Completed Not applicable Interventional Results available

HFNC Flow Titration and Effort of Breathing in the PICU

NCT02793674
View directory record Official record
Conditions
High Flow Nasal Cannula
Interventions
Fisher & Paykel high flow nasal cannula, Vapotherm high flow nasal cannula
Device
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
Up to 3 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 24, 2026, 4:40 AM EDT